Number of the records: 1
MHC class I status of tumours and design of immunotherapeutic strategies
- 1.0191677 - UMG-J 20033192 RIV NL eng J - Journal Article
Bubeník, Jan - Vonka, V.
MHC class I status of tumours and design of immunotherapeutic strategies.
Immunology Letters. Roč. 90, 2-3 (2003), s. 177-178. ISSN 0165-2478. E-ISSN 1879-0542
R&D Projects: GA MZd NC7148; GA MZd NC3707; GA MZd NC6957; GA MZd NC7552; GA ČR GA301/01/0985; GA AV ČR IAA5052203
Institutional research plan: CEZ:AV0Z5052915
Keywords : MHC * beta2-mikroglobulin * immunotherapeutic strategies
Subject RIV: FB - Endocrinology, Diabetology, Metabolism, Nutrition
Impact factor: 1.710, year: 2003
Attention should be paid to the MHC class I status of neoplasms during the design of immunotherapy protocols. For therapy of MHC class I deficient tumours, cytokines such as IFN gamma, IL-12, IL-2, GM-CSF, either exogenous or produced by gene-modified vaccines, should be considered. The therapeutic role of the induction of MHC class I expression by demethylation and acetylation agents should also be investigated.
Permanent Link: http://hdl.handle.net/11104/0087415
Number of the records: 1